Subcutaneous Injectable Drugs Hypersensitivity and Desensitization: Insulin and Monoclonal Antibodies

Sevim Bavbek; Min Jung Lee

doi:10.1016/j.iac.2017.06.001

Subcutaneous Injectable Drugs Hypersensitivity and Desensitization: Insulin and Monoclonal Antibodies

Sevim Bavbek, Min Jung Lee

Research output: Contribution to journal › Review article › peer-review

10 Scopus citations

Abstract

Injectable drugs, including monoclonal antibodies, are becoming crucial components in the management of chronic diseases. The most common side effects are local reactions at the site of administration. With the increased and prolonged use of these medications, we are seeing increased reports of hypersensitivity reactions. The aim of this article is to discuss the signs and symptoms of these reactions as well as management, which may involve desensitization for 3 commonly encountered injectable drugs: tumor necrosis factor-α inhibitors (etanercept and adalimumab), insulin, and omalizumab.

Original language	English (US)
Pages (from-to)	761-771
Number of pages	11
Journal	Immunology and Allergy Clinics of North America
Volume	37
Issue number	4
DOIs	https://doi.org/10.1016/j.iac.2017.06.001
State	Published - Nov 2017

Keywords

Adalimumab
Etanercept
Injection site reactions
Insulin
MoAbs
Omalizumab
Systemic hypersensitivity reactions
TNF-α inhibitors

ASJC Scopus subject areas

Immunology and Allergy
Immunology

Access to Document

10.1016/j.iac.2017.06.001

Cite this

@article{2744337f1a3f448b867ed0f7446893a1,

title = "Subcutaneous Injectable Drugs Hypersensitivity and Desensitization: Insulin and Monoclonal Antibodies",

abstract = "Injectable drugs, including monoclonal antibodies, are becoming crucial components in the management of chronic diseases. The most common side effects are local reactions at the site of administration. With the increased and prolonged use of these medications, we are seeing increased reports of hypersensitivity reactions. The aim of this article is to discuss the signs and symptoms of these reactions as well as management, which may involve desensitization for 3 commonly encountered injectable drugs: tumor necrosis factor-α inhibitors (etanercept and adalimumab), insulin, and omalizumab.",

keywords = "Adalimumab, Etanercept, Injection site reactions, Insulin, MoAbs, Omalizumab, Systemic hypersensitivity reactions, TNF-α inhibitors",

author = "Sevim Bavbek and Lee, {Min Jung}",

note = "Publisher Copyright: {\textcopyright} 2017 Elsevier Inc.",

year = "2017",

month = nov,

doi = "10.1016/j.iac.2017.06.001",

language = "English (US)",

volume = "37",

pages = "761--771",

journal = "Immunology and Allergy Clinics of North America",

issn = "0889-8561",

publisher = "W.B. Saunders Ltd",

number = "4",

}

TY - JOUR

T1 - Subcutaneous Injectable Drugs Hypersensitivity and Desensitization

T2 - Insulin and Monoclonal Antibodies

AU - Bavbek, Sevim

AU - Lee, Min Jung

PY - 2017/11

Y1 - 2017/11

N2 - Injectable drugs, including monoclonal antibodies, are becoming crucial components in the management of chronic diseases. The most common side effects are local reactions at the site of administration. With the increased and prolonged use of these medications, we are seeing increased reports of hypersensitivity reactions. The aim of this article is to discuss the signs and symptoms of these reactions as well as management, which may involve desensitization for 3 commonly encountered injectable drugs: tumor necrosis factor-α inhibitors (etanercept and adalimumab), insulin, and omalizumab.

AB - Injectable drugs, including monoclonal antibodies, are becoming crucial components in the management of chronic diseases. The most common side effects are local reactions at the site of administration. With the increased and prolonged use of these medications, we are seeing increased reports of hypersensitivity reactions. The aim of this article is to discuss the signs and symptoms of these reactions as well as management, which may involve desensitization for 3 commonly encountered injectable drugs: tumor necrosis factor-α inhibitors (etanercept and adalimumab), insulin, and omalizumab.

KW - Adalimumab

KW - Etanercept

KW - Injection site reactions

KW - Insulin

KW - MoAbs

KW - Omalizumab

KW - Systemic hypersensitivity reactions

KW - TNF-α inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85027585689&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027585689&partnerID=8YFLogxK

U2 - 10.1016/j.iac.2017.06.001

DO - 10.1016/j.iac.2017.06.001

M3 - Review article

C2 - 28965639

AN - SCOPUS:85027585689

SN - 0889-8561

VL - 37

SP - 761

EP - 771

JO - Immunology and Allergy Clinics of North America

JF - Immunology and Allergy Clinics of North America

IS - 4

ER -

Subcutaneous Injectable Drugs Hypersensitivity and Desensitization: Insulin and Monoclonal Antibodies

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this